首页> 外文期刊>JMIR Research Protocols >Mobile Application to Promote Adherence to Oral Chemotherapy and Symptom Management: A Protocol for Design and Development
【24h】

Mobile Application to Promote Adherence to Oral Chemotherapy and Symptom Management: A Protocol for Design and Development

机译:促进对口服化疗和症状管理的依从性的移动应用程序:设计和开发协议

获取原文
           

摘要

Background Oral chemotherapy is increasingly used in place of traditional intravenous chemotherapy to treat patients with cancer. While oral chemotherapy includes benefits such as ease of administration, convenience, and minimization of invasive infusions, patients receive less oversight, support, and symptom monitoring from clinicians. Additionally, adherence is a well-documented challenge for patients with cancer prescribed oral chemotherapy regimens. With the ever-growing presence of smartphones and potential for efficacious behavioral intervention technology, we created a mobile health intervention for medication and symptom management. Objective The objective of this study was to develop and evaluate the usability and acceptability of a smartphone app to support adherence to oral chemotherapy and symptom management in patients with cancer. Methods We used a 5-step development model to create a comprehensive mobile app with theoretically informed content. The research and technical development team worked together to develop and iteratively test the app. In addition to the research team, key stakeholders including patients and family members, oncology clinicians, health care representatives, and practice administrators contributed to the content refinement of the intervention. Patient and family members also participated in alpha and beta testing of the final prototype to assess usability and acceptability before we began the randomized controlled trial. Results We incorporated app components based on the stakeholder feedback we received in focus groups and alpha and beta testing. App components included medication reminders, self-reporting of medication adherence and symptoms, an education library including nutritional information, Fitbit integration, social networking resources, and individually tailored symptom management feedback. We are conducting a randomized controlled trial to determine the effectiveness of the app in improving adherence to oral chemotherapy, quality of life, and burden of symptoms and side effects. At every stage in this trial, we are engaging stakeholders to solicit feedback on our progress and next steps. Conclusions To our knowledge, we are the first to describe the development of an app designed for people taking oral chemotherapy. The app addresses many concerns with oral chemotherapy, such as medication adherence and symptom management. Soliciting feedback from stakeholders with broad perspectives and expertise ensured that the app was acceptable and potentially beneficial for patients, caregivers, and clinicians. In our development process, we instantiated 7 of the 8 best practices proposed in a recent review of mobile health app development. Our process demonstrated the importance of effective communication between research groups and technical teams, as well as meticulous planning of technical specifications before development begins. Future efforts should consider incorporating other proven strategies in software, such as gamification, to bolster the impact of mobile health apps. Forthcoming results from our randomized controlled trial will provide key data on the effectiveness of this app in improving medication adherence and symptom management. Trial Registration ClinicalTrials.gov {"type":"clinical-trial","attrs":{"text":"NCT02157519","term_id":"NCT02157519"}} NCT02157519 ; https://clinicaltrials.gov/ct2/show/ {"type":"clinical-trial","attrs":{"text":"NCT02157519","term_id":"NCT02157519"}} NCT02157519 (Archived by WebCite at http://www.webcitation.org/6prj3xfKA).
机译:背景技术口服化疗已越来越多地用于代替传统的静脉化疗来治疗癌症患者。口服化学疗法的好处包括易于管理,方便和减少侵入性输液,而患者从临床医生那里得到的监督,支持和症状监测较少。此外,依从性是癌症处方的口服化疗方案患者的有据可查的挑战。随着智能手机的不断增长以及有效行为干预技术的潜力,我们创建了用于药物和症状管理的移动健康干预。目的这项研究的目的是开发和评估智能手机应用程序的可用性和可接受性,以支持癌症患者坚持口服化疗和症状管理。方法我们使用了五步开发模型来创建具有理论知识内容的综合移动应用程序。研究和技术开发团队共同开发和迭代测试了该应用程序。除研究团队外,主要的利益相关者包括患者和家庭成员,肿瘤临床医生,卫生保健代表和实践管理人员为干预措施的内容优化做出了贡献。在我们开始随机对照试验之前,患者和家属还参加了最终原型的alpha和beta测试,以评估可用性和可接受性。结果我们根据在焦点小组以及alpha和beta测试中收到的利益相关者的反馈,合并了应用程序组件。应用程序组件包括药物提醒,药物依从性和症状的自我报告,包含营养信息,Fitbit集成,社交网络资源以及个性化症状管理反馈的教育库。我们正在进行一项随机对照试验,以确定该应用程序在改善对口服化学疗法的依从性,生活质量以及症状和副作用负担方面的有效性。在该试验的每个阶段,我们都在与利益相关方合作,征求有关我们的进展和后续步骤的反馈。结论据我们所知,我们是第一个描述为接受口服化学疗法的人设计的应用程序的开发。该应用程序解决了口服化疗的许多问题,例如药物依从性和症状管理。征求利益相关者的广泛观点和专业意见,可以确保该应用程序可以被接受,并且可能对患者,护理人员和临床医生有益。在我们的开发过程中,我们实例化了最近对移动医疗应用程序开发进行回顾的8种最佳实践中的7种。我们的过程证明了研究小组与技术团队之间进行有效沟通的重要性,以及在开发开始之前精心策划技术规格的重要性。未来的工作应考虑在软件中纳入其他经过验证的策略,例如游戏化,以增强移动医疗应用程序的影响。来自我们的随机对照试验的即将出现的结果将提供有关此应用程序在改善药物依从性和症状管理方面的有效性的关键数据。试验注册ClinicalTrials.gov {“ type”:“ clinical-trial”,“ attrs”:{“ text”:“ NCT02157519”,“ term_id”:“ NCT02157519”}} NCT02157519; https://clinicaltrials.gov/ct2/show/ {“ type”:“ clinical-trial”,“ attrs”:{“ text”:“ NCT02157519”,“ term_id”:“ NCT02157519”}} NCT02157519(由WebCite存档在http://www.webcitation.org/6prj3xfKA)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号